Literature DB >> 25784721

Salmeterol Efficacy and Bias in the Activation and Kinase-Mediated Desensitization of β2-Adrenergic Receptors.

Luis E Gimenez1, Faiza Baameur1, Sharat J Vayttaden1, Richard B Clark2.   

Abstract

Salmeterol is a long-acting β2-adrenergic receptor (β2AR) agonist that is widely used as a bronchodilator for the treatment of persistent asthma and chronic obstructive pulmonary disease in conjunction with steroids. Previous studies demonstrated that salmeterol showed weak efficacy for activation of adenylyl cyclase; however, its efficacy in the complex desensitization of the β2AR remains poorly understood. In this work, we provide insights into the roles played by the G protein-coupled receptor kinase/arrestin and protein kinase A in salmeterol-mediated desensitization through bioluminescence resonance energy transfer (BRET) studies of liganded-β2AR binding to arrestin and through kinetic studies of cAMP turnover. First, BRET demonstrated a much reduced efficacy for salmeterol recruitment of arrestin to β2AR relative to isoproterenol. The ratio of BRETISO/BRETSALM after 5-minute stimulation was 20 and decreased to 5 after 35 minutes, reflecting a progressive decline in BRETISO and a stable BRETSALM. Second, to assess salmeterol efficacy for functional desensitization, we examined the kinetics of salmeterol-induced cAMP accumulation (0-30 minutes) in human airway smooth muscle cells in the presence and absence of phosphodiesterase inhibition. Analysis of shaping of cAMP turnover for both agonists demonstrated significant salmeterol desensitization, although it was reduced relative to isoproterenol. Using an isoproterenol rescue protocol after either short-term (10 minutes) or long-term (2 and 14 hours) salmeterol pretreatments, we found that salmeterol progressively depressed isoproterenol stimulation but did not prevent subsequent rescue by isoproterenol and additional isoproterenol-mediated desensitization. Our findings reveal a complex efficacy for functional desensitization, demonstrating that although salmeterol shows weak efficacy for adenylyl cyclase activation and G protein-coupled receptor kinase/arrestin-mediated desensitization, it acts as a strong agonist in highly amplified protein kinase A-mediated events. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25784721      PMCID: PMC4429720          DOI: 10.1124/mol.114.096800

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  53 in total

1.  Crystal structures of the luciferase and green fluorescent protein from Renilla reniformis.

Authors:  Andreas Markus Loening; Timothy David Fenn; Sanjiv Sam Gambhir
Journal:  J Mol Biol       Date:  2007-10-03       Impact factor: 5.469

2.  Beta-arrestins specifically constrain beta2-adrenergic receptor signaling and function in airway smooth muscle.

Authors:  Deepak A Deshpande; Barbara S Theriot; Raymond B Penn; Julia K L Walker
Journal:  FASEB J       Date:  2008-03-12       Impact factor: 5.191

3.  Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy.

Authors:  Emma T van der Westhuizen; Billy Breton; Arthur Christopoulos; Michel Bouvier
Journal:  Mol Pharmacol       Date:  2013-12-23       Impact factor: 4.436

Review 4.  β2-agonist therapy in lung disease.

Authors:  Mario Cazzola; Clive P Page; Paola Rogliani; M Gabriella Matera
Journal:  Am J Respir Crit Care Med       Date:  2013-04-01       Impact factor: 21.405

Review 5.  How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.

Authors:  Mark A Giembycz; Robert Newton
Journal:  Clin Chest Med       Date:  2013-12-12       Impact factor: 2.878

6.  Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting beta2-adrenoceptor agonist exposure.

Authors:  Gustavo Nino; Aihua Hu; Judith S Grunstein; Michael M Grunstein
Journal:  J Allergy Clin Immunol       Date:  2010-04-14       Impact factor: 10.793

7.  Differential expression of the beta-adrenergic receptor modifies agonist stimulation of adenylyl cyclase: a quantitative evaluation.

Authors:  B S Whaley; N Yuan; L Birnbaumer; R B Clark; R Barber
Journal:  Mol Pharmacol       Date:  1994-03       Impact factor: 4.436

8.  Glucocorticosteroids and β₂-adrenoceptor agonists synergize to inhibit airway smooth muscle remodeling.

Authors:  Bart G J Dekkers; Adnan Pehlic; Raissa Mariani; I Sophie T Bos; Herman Meurs; Johan Zaagsma
Journal:  J Pharmacol Exp Ther       Date:  2012-06-08       Impact factor: 4.030

9.  Manipulation of very few receptor discriminator residues greatly enhances receptor specificity of non-visual arrestins.

Authors:  Luis E Gimenez; Sergey A Vishnivetskiy; Faiza Baameur; Vsevolod V Gurevich
Journal:  J Biol Chem       Date:  2012-07-11       Impact factor: 5.157

10.  Quantitative modeling of GRK-mediated beta2AR regulation.

Authors:  Sharat J Vayttaden; Jacqueline Friedman; Tuan M Tran; Thomas C Rich; Carmen W Dessauer; Richard B Clark
Journal:  PLoS Comput Biol       Date:  2010-01-22       Impact factor: 4.475

View more
  11 in total

Review 1.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 2.  A cellular perspective of bias at G protein-coupled receptors.

Authors:  Thomas J Fernandez; Monica De Maria; Braden T Lobingier
Journal:  Protein Sci       Date:  2020-04-27       Impact factor: 6.725

Review 3.  GPCR desensitization: Acute and prolonged phases.

Authors:  Sudarshan Rajagopal; Sudha K Shenoy
Journal:  Cell Signal       Date:  2017-01-28       Impact factor: 4.315

4.  β2 -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the β2 -adrenoceptor with possible implications for the treatment of asthma.

Authors:  Francesco De Pascali; Michael Ippolito; Emily Wolfe; Konstantin E Komolov; Nathan Hopfinger; Douglas Lemenze; Nicholas Kim; Roger S Armen; Steven S An; Charles P Scott; Jeffrey L Benovic
Journal:  Br J Pharmacol       Date:  2022-07-19       Impact factor: 9.473

5.  The stimulation and inhibition of beta-2 adrenergic receptor on the inflammatory responses of ovary and immune system in the aged laying hens.

Authors:  Ali Hatefi; Ahmad Zare Shahneh; Zarbakht Ansari Pirsaraie; Ali Mohammad Alizadeh; Mohammad Pouya Atashnak; Reza Masoudi; Frederic Pio
Journal:  BMC Vet Res       Date:  2021-05-22       Impact factor: 2.741

6.  Analyzing kinetic signaling data for G-protein-coupled receptors.

Authors:  Sam R J Hoare; Paul H Tewson; Anne Marie Quinn; Thomas E Hughes; Lloyd J Bridge
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.379

7.  Structural insights into binding specificity, efficacy and bias of a β2AR partial agonist.

Authors:  Matthieu Masureel; Yaozhong Zou; Louis-Philippe Picard; Emma van der Westhuizen; Jacob P Mahoney; João P G L M Rodrigues; Thomas J Mildorf; Ron O Dror; David E Shaw; Michel Bouvier; Els Pardon; Jan Steyaert; Roger K Sunahara; William I Weis; Cheng Zhang; Brian K Kobilka
Journal:  Nat Chem Biol       Date:  2018-10-16       Impact factor: 15.040

8.  Allosteric Effect of Nanobody Binding on Ligand-Specific Active States of the β2 Adrenergic Receptor.

Authors:  Yue Chen; Oliver Fleetwood; Sergio Pérez-Conesa; Lucie Delemotte
Journal:  J Chem Inf Model       Date:  2021-11-15       Impact factor: 4.956

9.  Discovery of β-arrestin-biased β2-adrenoceptor agonists from 2-amino-2-phenylethanol derivatives.

Authors:  Anthony Yiu-Ho Woo; Xin-Yue Ge; Li Pan; Gang Xing; Yong-Mei Mo; Rui-Juan Xing; Xiao-Ran Li; Yu-Yang Zhang; Irving W Wainer; Mao-Sheng Cheng; Rui-Ping Xiao
Journal:  Acta Pharmacol Sin       Date:  2019-01-14       Impact factor: 6.150

Review 10.  Biased agonism at β-adrenergic receptors.

Authors:  Michael Ippolito; Jeffrey L Benovic
Journal:  Cell Signal       Date:  2020-12-29       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.